___

• Kluytmans J, Van Belkum A,Verburg H. Nasal carriage of S.aureus. Epidemiology, underlying mechanisms and associated risk .Clin Microbiol Rev, 1997; 10 (3): 505-20.
• Boelaert JR, Van Landuyt HW, Godard CA, et al.. Nasal mupirocin omtment decreases the incidence of S.aureus bacteremıa in haemodialysis patients, Nephrol Dial Transplant, 1993; 8: 235-9.
• Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicenter prospective survey. Nephrol Dial Transplant, 1995;
• Boaelaert JR: S.aureus infection in haemodialysis patient. Mupirociin as a topical strategy against nasal carrıage. A review J Chemother, 1994; 2: 19-24.
• Grady M, Cullen JJ. Preventing postoperative Staphylococcus infections: an update. Surg Technol Int, 2003; 11:57-60.
• National Committe for Clinical Laboratory Standarts: Performance Standarts for Antimicrobial Disk Susceptibility Tests. NCCLS Document, 6th edition: Wayne Pa, Approved Standart M2-A5.(M100-S7) (2002).
• Koziol-Montewka M, Chudnicka A, Ksiazek A, Majdan M. Rate of S.aureus nasal carriage in immunocompromised patients receiving haemodialysis treatment. Int J Antimicrob Agents, 2001;18: 193-6.
• Doebbeling BN, Reagen DR, Pfaller MA, Houston AK, Hollis RJ, Wenzel RP. Long term efficiency of intra nasal mupirocin omtment: A prospective chort study of Staphyiococcus aureus carrıage. Arch Intern Med, 1994; 154: 1505-8.
• Kadanalı A, Altoparlak Ü, Pirimoğlu S. Hemodiyaliz hastalarında nazal S.aureus taşıyıcılığı ve suşların antibi- yotik duyarlılığı. ANKEM derg, 2002; 16(4): 470-3.
• Kökoğlu ÖF, Geyik MF, Ayaz C, Uçmak H, Hoşoğlu S. Dicle Üniversitesi Hastanesi çalışanları ve diyaliz hastalarında S.aureus taşıyıcılığı ve antibiyotik duyar- lılığının araştırılması. İnfek derg, 2003; 17(4): 443-6.
• Mutlu B, Bilen N, Tansel Ö, Gürler DB, Coşkunkan F, Vahaboğlu H. Hemodiyaliz hastaları ve persone- linde S.aureus kolonizasyonu araştırılması. İnfek derg, 2002;16(3): 315-7.
• Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D'Agata EM. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis,.2003; 15;37(12): 1629-38.
• Bonomo RA, Rice D, Whalen C et al.. Risk factor associated with permanent acces site infections in chronic hemodialysis patients. Infect Cont Hosp Epidermiol, 1997;11: 757-62.
• Tammelin A, Klotz F, Hambraeus A, Stahle E, Ransjo U. Nasal and hand carriage of Staphylococcus aureus in staff at a Department for Thoracic and Cardiovascular Surgery: endogenous or exogenous source? Infect Control Hosp Epidemiol, 2003; 24(9): 686-9.
• Ena J, Boalaert JR, Boyken LD, Van Landuyt HW, Godard CA, Hervvoldt LA. Epıdemıology of infections in nasal carriers of S.aureus on haemodialysis. Intect Control Hosp Epidemiol, 1994;15: 78-81.
• Diler T, Altanlar N, Emekdaş G,Kocabeyoğlu Ö, A- kın A. Hastane ortam ve cihazlarından izole edilen stafilokok suşlarında oksasilin, fusidik asit,mupirosin ve değişik diğer antibiyotiklere direnç. ANKEM Derg, 1999; 13: 53-6.
• Kaya D, Kaptanoğlu S, Kiraz N, Kaya E. Mupirosinin yara örneklerinden izole edilen stafilokok suşlarına karşı invitro etkinliği. ANKEM Derg, 1994; 8: 102-5.
• Entenza JM, Fluckiger U, Glauser MP, Moreillion P. Antibiotic treatment of experimental endocarditis due to methicillin resistant S.epidermidis. J infect Dis, 1994; 170:100-9.
• Yu VL, Goetz A, Wagener M, et al. Stapylococcus aureus nasal carrıage and infection in patients on haemodialysis. Efficacy of antibiotic prophylaxis, N Engl Med, 1986;315:91-6.
• Hudson ÎR. The efficacy of intranasal mupirocin in the preventıon of staphylococcal infections: a revievv of recent experience. J Hosp Infect, 1984; 27: 81-98.
• Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence- based review. Clin Infect Dis, 2003; 37(7): 933-8.
• Muro K, Lim PB. A comparıson of mupirocin and rıfampin in snort-term eradıcation of Staphyiococcus aureus nasal carrıage in haemodialysis patients. JAm Soc Nephrol, 1991; 2: 340-5.
• Zimakoff J,Bangsgaard PF,Bergen L et al.. S.aureus carrıage and infections among patients in four haemo and peritoneal-dialysis center in Denmark. J Hosp Infect, 1996; 33: 289-300.
• Kauffman CA, Terpenning MS, He X, et al.. Attempts to eraaicate methıciliın-resistanî Slaphy/ococcus aureus from a long term-care facılity with the use of mupirocin ointment. Am J Med, 1993;
• Mitrokhin SD: Mupirocin. prophylaxis of hospital- acquired infections due to Staphylococcus aureus and sanitation of hospital environment. Antibiot Khimioter, 2003; 48:13-9.
• Panililio A, Culuer RP, Gayes SP. The national nosocomial infection surveillance system. Methicillin resistant S.aureus in U.S hospitals 1975-1991. Infect Cont Hosp Epidermiol, 1992; 13: 582-6.